Intravenous iron can be an important treatment when iron deficiency anemia cannot be corrected adequately with oral iron. But the choice of IV iron formulation matters. On September 1, 2026, the U.S. Food and Drug Administration announced a new boxed warning for ferric carboxymaltose, marketed as Injectafer, because it can cause serious symptomatic hypophosphatemia—abnormally low blood phosphate. The warning should inform conversations about treatment without being misapplied to every IV iron product.
Why would someone need IV iron?
Iron deficiency may result from blood loss, inadequate intake, impaired absorption or increased requirements. A clinician first evaluates whether anemia or iron deficiency is present and why it developed. A complete blood count, ferritin and other iron studies can be useful, interpreted in clinical context. Iron replacement does not eliminate the need to investigate potentially important causes such as gastrointestinal bleeding.
The American Gastroenterological Association’s 2024 clinical practice update supports IV iron when oral iron is not tolerated, ferritin does not improve with a trial of oral therapy or a condition makes absorption unlikely. Oral iron remains appropriate for many patients. IV treatment is not a general energy infusion for people without a demonstrated indication.
What is hypophosphatemia?
Phosphate is needed for cellular energy, muscle function and bone health. Low levels can cause fatigue, weakness, muscle or bone pain and, when severe, neurological or cardiac complications. Prolonged severe deficiency can contribute to osteomalacia and fractures. Some symptoms overlap with iron deficiency itself, making the connection easy to miss.
The FDA specifically strengthened ferric carboxymaltose labeling after reviewing reports of symptomatic hypophosphatemia, including cases after a single infusion and after repeated courses. The agency reported that phosphate monitoring was performed in fewer than one in five ferric carboxymaltose administration episodes in the Sentinel data it evaluated. This is a safety signal and monitoring issue, not evidence that all patients receiving the drug will develop complications.
Who needs extra attention before repeat treatment?
According to the FDA communication, clinicians should check serum phosphate before a repeat ferric carboxymaltose course in patients at risk for low phosphate and in anyone receiving another course within three months. Existing hypophosphatemia should be corrected before treatment. Patients at risk of persistent low phosphate may need ongoing monitoring. The precise laboratory plan depends on formulation, clinical history and the product label.
Risk review may include nutritional status, malabsorption or inflammatory bowel disease, vitamin D-related problems, repeated dosing and symptoms suggestive of low phosphate. A clinician also reviews prior infusion reactions and other medical conditions. A phosphate level is not a substitute for evaluating whether IV iron is indicated in the first place.
Does this warning apply to every IV iron formulation?
No. The September 2026 FDA boxed-warning communication concerns ferric carboxymaltose. Other IV iron products have their own prescribing information, risks and administration requirements. All IV iron administration requires appropriate facilities and personnel to recognize and manage infusion reactions, and a patient should know which specific product is being considered.
The 2024 AGA update notes that true anaphylaxis with IV iron is rare and that many reactions are non-IgE infusion reactions. Rare does not mean impossible. A clinician should explain reaction symptoms, observation and emergency readiness.
Questions to ask before an iron infusion
Ask: What confirms my iron deficiency? Why is IV iron preferred over oral treatment? What is the exact drug formulation? Do I need baseline or follow-up phosphate testing? How will we know whether the treatment worked? And what investigation is planned to identify the cause of deficiency? Patients should promptly report new muscle weakness, bone pain, unusual fatigue or other concerning symptoms after treatment, especially after repeat courses.
Our iron infusion service page outlines the clinic’s evaluation pathway. This article is a focused safety update and does not imply that the practice uses ferric carboxymaltose or any particular brand.
Bottom line
IV iron can be clinically valuable when indicated. The FDA’s September 2026 action is a reminder that the exact formulation and a tailored monitoring plan matter, especially with repeated ferric carboxymaltose treatment.
Medical and regulatory references
- FDA Drug Safety Communication: Ferric Carboxymaltose Boxed Warning (September 1, 2026).
- AGA Clinical Practice Update: Management of Iron Deficiency Anemia (June 11, 2024).
- Expert consensus: IV iron uses, administration and management of reactions (American Journal of Hematology, 2024).
Medical information only. Do not begin or discontinue prescribed iron treatment based solely on this article.
